Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Monday, 16'th Feb 2026
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Axsome Therapeutics Stock Before Feb. 23?
09:00am, Thursday, 05'th Feb 2026
The healthcare company is set to release its fourth-quarter results later this month.
1 High-Flying Stock With More Upside Ahead
11:45am, Tuesday, 03'rd Feb 2026
Axsome Therapeutics' current product lineup has been driving solid revenue growth. The biotech should earn several approvals or label expansions in the next few years.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
07:00am, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
11:15am, Monday, 26'th Jan 2026
Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM
05:48am, Monday, 26'th Jan 2026
Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 30.7% during the undefined quarter, according to the company in its most recent
Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM
03:50am, Monday, 26'th Jan 2026
Cabot Wealth Management Inc. purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to its most recent 13F filing with the Securities and E
Ari Maizel Sells 7,500 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
04:58am, Sunday, 25'th Jan 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average
Nick Pizzie Sells 12,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
04:02am, Sunday, 25'th Jan 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CFO Nick Pizzie sold 12,000 shares of the company's stock in a transaction on Thursday, January 22nd. The shares were sold at an average pric
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline
06:38am, Saturday, 24'th Jan 2026
Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to e
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?
09:41am, Wednesday, 21'st Jan 2026
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
12:15pm, Friday, 16'th Jan 2026
AXSM doses the first patient in the phase III FORWARD study testing AXS-14 for fibromyalgia.
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 15'th Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MoneyShow's Best Investment Ideas For 2026: Part 2
04:20pm, Monday, 12'th Jan 2026
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
07:00am, Monday, 12'th Jan 2026
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively
